cerebral disease

By Targets:	Acyltransferase (1) Akt (1) Amyloid-β (3) Calcium Channel (1) Cholinesterase (ChE) (2) Dopamine Receptor (2) ERK (1) Fungal (1) GABA Receptor (1) Keap1-Nrf2 (1) mAChR (1) NO Synthase (1) Phosphodiesterase (PDE) (2) Sodium Channel (1) Trk Receptor (1)
By Research Areas:	Cancer (2) Cardiovascular Disease (5) Infection (1) Inflammation/Immunology (1) Metabolic Disease (2) Neurological Disease (18)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-153595

DAPK-IN-2

Others Cardiovascular Disease

DAPK-IN-2 is a DAPK inhibitor. DAPK-IN-2 can be used for the research of cerebral infarction and ischemic diseases .

DAPK-IN-2	Others	Cardiovascular Disease
DAPK-IN-2 is a DAPK inhibitor. DAPK-IN-2 can be used for the research of cerebral infarction and ischemic diseases .

HY-103479

GOAT-IN-1	Acyltransferase	Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
GOAT-IN-1 is an inhibitor of ghrelin O-acyltransferase (GOAT), which could be useful for the prophylaxis or treatment of obesity, diabetes, hyperlipidemia, metabolic, non-alcoholic fatty liver, steatohepatitis, sarcopenia, appetite control, alcohol/narcotic dependence, Alzheimer’s disease, Parkinson’s disease, cerebrovascular dementia, cerebral apoplexy, cerebral infarction, cardic disease, some kind of tumors.

HY-143333

Nrf2 activator-3	Keap1-Nrf2	Neurological Disease Inflammation/Immunology
Nrf2 activator-3 is a potent Nrf2 activator. Nrf2 activator-3 is used for cerebral ischemic injury research .

HY-117983

RU-505	Amyloid-β	Neurological Disease
RU-505 is an effective β-amyloid (Aβ)-fibrinogen interaction inhibitor with IC₅₀s of 5.00 and 2.72 μM in fluorescence polarization (FP) and AlphaLISA assays, respectively. RU-505 is highly permeable to the BBB. RU-505 reduces cerebral amyloid angiopathy (CAA). RU-505 can be used for the research of Alzheimer’s disease (AD) .

HY-B1680

Lithium citrate

Litarex

Lithium citrate reduces excessive intra-cerebral N-acetyl aspartate in Canavan disease .

Lithium citrate Litarex
Lithium citrate reduces excessive intra-cerebral N-acetyl aspartate in Canavan disease .

HY-P99022

Gantenerumab	Amyloid-β	Neurological Disease
Gantenerumab is a fully human anti-amyloid-β (Aβ) IgG1 monoclonal antibody demonstrates sustained cerebral amyloid-β binding. Gantenerumab can be used for Alzheimer's disease research .

HY-139427

3-Methylglutaconic acid β-Methylglutaconic acid	GABA Receptor	Cardiovascular Disease Neurological Disease Metabolic Disease
3-Methylglutaconic acid is the major metabolites accumulating in 3-Methylglutaconic aciduria (MGTA). 3-Methylglutaconic acid can induce lipid oxidative damage and protein oxidative. 3-Methylglutaconic acid decreases the non-enzymatic antioxidant defenses in cerebral cortex supernatants to elicit oxidative stress in the cerebral cortex. 3-Methylglutaconic acid can be used for brain damage disease research .

HY-107802

Breviscapine Breviscapinun	Others	Cardiovascular Disease
Breviscapine is a crude flavonoid extract of Breviscapine, which is more than 85% of the active ingredient, Breviscapine. Breviscapine has a wide range of cardiovascular pharmacological activities, such as increasing blood flow, improving microcirculation, dilating blood vessels, reducing blood viscosity, promoting fibrinolysis, inhibiting platelet aggregation and thrombosis. Breviscapine has been used in the study of cerebral infarction and its sequelae, cerebral thrombosis, coronary heart disease and angina pectoris .

HY-133712

Yonkenafil Tunodafil	Phosphodiesterase (PDE)	Neurological Disease
Yonkenafil (Tunodafil), a novel phosphodiesterase 5 (PDE5) inhibitor, is effective in reducing cerebral infarction, neurological deficits, edema, and neuronal damage in the infarcted area. Yonkenafil may improve cognitive function by modulating neurogenesis and has a potential therapeutic effect on Alzheimer's disease .

HY-107661

Arundic Acid 1 Publications Verification ONO-2506; (R)-2-Propyloctanoic acid	Others	Neurological Disease
Arundic acid (ONO-2506) is an astrocyte-modulating agent, which delays the expansion of cerebral infarcts by modulating the activation of astrocytes through inhibition of S-100β synthesis. Arundic acid has the potential for stroke and Alzheimer’s disease research .

HY-125095

Yonkenafil hydrochloride Tunodafil hydrochloride	Phosphodiesterase (PDE)	Cardiovascular Disease Neurological Disease
Yonkenafil (Tunodafil) hydrochloride, a novel phosphodiesterase 5 (PDE5) inhibitor, is effective in reducing cerebral infarction, neurological deficits, edema, and neuronal damage in the infarcted area. Yonkenafil (Tunodafil) hydrochloride may improve cognitive function by modulating neurogenesis and has a potential therapeutic effect on Alzheimer's disease .

HY-N11911

Verazine (-)-Verazine	Fungal	Infection Neurological Disease
Verazine ((-)-Verazine) is an anti-Fungal Agent that can be found in the dried roots and rhizoma of Veratrum maackii Regel. Verazine causes DNA damage in the cerebellum and cerebral cortex of mice in a dose-dependent manner. Verazine can be used in the study of fungal infections and neurological diseases .

HY-135478

LY393615 NCC1048	Calcium Channel Sodium Channel	Neurological Disease
LY393615 (NCC1048) is a novel neuronal Ca ²⁺ (calcium channel) and Na ⁺ channel (sodium channel) blocker with IC₅₀s of 1.9 μΜ and 5.2 μΜ for α1A and α1B calcium channel subunits. LY393615 has good brain penetration and neuroprotective effects in models of in cerebral ischemia that can be used for neurological disease research .

HY-130452

NOS1-IN-1	NO Synthase	Neurological Disease
NOS1-IN-1 is a selective and cell-permeable nNOS inhibitor with a K_i of 120 nM. NOS1-IN-1 exhibits 2617-fold and 325-fold selectivity over eNOS (K_i=39 μM) and iNOS (K_i=325 μM) , respectively . NOS1-IN-1 can be used for the research of neurological disease, including cerebral palsy (CP) .

HY-19651B

Zanapezil fumarate TAK-147 fumarate	Cholinesterase (ChE)	Neurological Disease
Zanapezil (TAK-147) fumarate is a potent, reversible and selective acetylcholine esterase (AChE) inhibitor. Zanapezil fumarate shows a potent and reversible inhibition of AChE activity in homogenates of the rat cerebral cortex (IC₅₀=51.2 nM). Zanapezil fumarate shows a moderate inhibition of muscarinic M1 and M2 receptor binding with K_i values of 234 and 340 nM, respectively. Zanapezil fumarate can be used for the research of early stages of Alzheimer's disease (AD) .

HY-19651

Zanapezil free base TAK-147 free base	Cholinesterase (ChE)	Neurological Disease
Zanapezil (TAK-147) free base is a potent, reversible and selective acetylcholine esterase (AChE) inhibitor. Zanapezil free base shows a potent and reversible inhibition of AChE activity in homogenates of the rat cerebral cortex (IC₅₀=51.2 nM). Zanapezil free base shows a moderate inhibition of muscarinic M1 and M2 receptor binding with K_i values of 234 and 340 nM, respectively. Zanapezil free base can be used for the research of early stages of Alzheimer's disease (AD) .

HY-121833

Gambogic amide	Trk Receptor Akt ERK	Neurological Disease Cancer
Gambogic amide is a potent and selective agonist of TrkA and also induces its tyrosine phosphorylation and activation of downstream signaling, including Akt and MAPK. Gambogic amide specifically interacts with the cytoplasmic juxtamembrane domain of the TrkA receptor and triggers its dimerization, leading to activation. Gambogic amide has neuroprotective activity preventing glutamate-induced neuronal cell death. Gambogic amide has improved efficacy in a transient middle cerebral artery occlusion model of stroke and could be used to study neurodegenerative diseases and stroke .

HY-P1047

β-Sheet Breaker Peptide iAβ5 [Pro18, Asp21] β-Amyloid (17-21)	Amyloid-β	Neurological Disease
β-Sheet Breaker Peptide iAβ5 is a potent degrader of cerebral amyloid-beta (Abeta). Abeta deposition is associatied with the Alzheimer disease (AD), due to its related toxicity linked to its beta-sheet conformation and/or aggregation. β-Sheet Breaker Peptide iAβ5 reproducibly induces in vivo disassembly of fibrillar amyloid deposits. Thus, β-Sheet Breaker Peptide iAβ5 prevents and/or reverses neuronal shrinkage caused by Abeta, and reduces the extent of interleukin-1beta positive microglia-like cells that surround the Abeta deposits. β-Sheet Breaker Peptide iAβ5 reduces the size and/or number of cerebral amyloid plaques in AD. β-Sheet Breaker Peptide iAβ5 labeled by hydrophobic benzyl alcohol (HBA) tag, can be used for quantitative assay by showing vivid blue color under acidic conditions .

HY-118342

PQCA	mAChR	Neurological Disease
PQCA is a highly selective and potent muscarinic M1 receptor positive allosteric modulator. PQCA has an EC₅₀ value of 49 nM and 135 nM on rhesus and human M1 receptor, respectively. PQCA is inactive for other muscarinic receptors. PQCA has potential to reduce the cognitive deficits associated with Alzheimer's disease .

HY-17355

Pramipexole dihydrochloride 5 Publications Verification	Dopamine Receptor	Neurological Disease
Pramipexole dihydrochloride is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with K_is of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D₂, D₃ and D₄ receptors, respectively. Pramipexole dihydrochloride can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS) .

HY-B0410

Pramipexole 5 Publications Verification	Dopamine Receptor	Neurological Disease
Pramipexole is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with K_is of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D₂, D₃ and D₄ receptors, respectively. Pramipexole can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS) .

Cat. No.	Product Name	Target	Research Area

HY-P1047

β-Sheet Breaker Peptide iAβ5 [Pro18, Asp21] β-Amyloid (17-21)	Amyloid-β	Neurological Disease
β-Sheet Breaker Peptide iAβ5 is a potent degrader of cerebral amyloid-beta (Abeta). Abeta deposition is associatied with the Alzheimer disease (AD), due to its related toxicity linked to its beta-sheet conformation and/or aggregation. β-Sheet Breaker Peptide iAβ5 reproducibly induces in vivo disassembly of fibrillar amyloid deposits. Thus, β-Sheet Breaker Peptide iAβ5 prevents and/or reverses neuronal shrinkage caused by Abeta, and reduces the extent of interleukin-1beta positive microglia-like cells that surround the Abeta deposits. β-Sheet Breaker Peptide iAβ5 reduces the size and/or number of cerebral amyloid plaques in AD. β-Sheet Breaker Peptide iAβ5 labeled by hydrophobic benzyl alcohol (HBA) tag, can be used for quantitative assay by showing vivid blue color under acidic conditions .

HY-P5452

PKCd (8-17)	Peptides	Others
PKCd (8-17) is a biological active peptide. (This peptide is derived from the V1 domain of protein kinase C (PKC)d. It inhibits phorbol 12-myristate 13-acetate (PMA)-induced PKCd translocation and activation. Inhibition of PKCd reduces ischemia damage in cardiac and cerebral cells, induces proliferation of fibroblasts, and inhibits graft coronary artery disease in mice.)

HY-P5331

[Asn23]-beta-Amyloid (1-42), iowa mutation	Peptides	Others
[Asn23]-beta-Amyloid (1-42), iowa mutation is a biological active peptide. (Several mutations in the beta amyloid precursor gene cause autosomal dominant Alzheimer's Disease in a number of kindreds. The Iowa mutation, where Asp 23 is replaced with Asn, is associated with severe cerebral amyloid beta-protein angiopathy (CAA). The affected individuals share a missense mutation in APP at position 694. The mutated beta-amyloid peptide aggregates more rapidly and forms toxic fibrils.)

HY-P5365

[Asn23] β-Amyloid (1-40), Iowa mutation	Peptides	Others
[Asn23] β-Amyloid (1-40), Iowa mutation is a biological active peptide. (Several mutations in the beta amyloid precursor gene cause autosomal dominant Alzheimer's Disease in a number of kindreds. The Iowa mutation, where Asp 23 is replaced with Asn, is associated with severe cerebral amyloid beta-protein angiopathy (CAA). The affected individuals share a missense mutation in APP at position 694. The mutated beta-amyloid peptide aggregates more rapidly and forms toxic fibrils.)

Cat. No.	Product Name	Target	Research Area

HY-P99022

Gantenerumab	Amyloid-β	Neurological Disease
Gantenerumab is a fully human anti-amyloid-β (Aβ) IgG1 monoclonal antibody demonstrates sustained cerebral amyloid-β binding. Gantenerumab can be used for Alzheimer's disease research .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-107802

Breviscapine Breviscapinun	Structural Classification Natural Products Source classification Plants Compositae Erigeron breviscapus (Vant.) Hand.-Mazz.	Others
Breviscapine is a crude flavonoid extract of Breviscapine, which is more than 85% of the active ingredient, Breviscapine. Breviscapine has a wide range of cardiovascular pharmacological activities, such as increasing blood flow, improving microcirculation, dilating blood vessels, reducing blood viscosity, promoting fibrinolysis, inhibiting platelet aggregation and thrombosis. Breviscapine has been used in the study of cerebral infarction and its sequelae, cerebral thrombosis, coronary heart disease and angina pectoris .

HY-N11911

Verazine (-)-Verazine	Structural Classification Alkaloids Other Alkaloids Source classification Veratrum maackii Regel Plants Melanthiaceae	Fungal
Verazine ((-)-Verazine) is an anti-Fungal Agent that can be found in the dried roots and rhizoma of Veratrum maackii Regel. Verazine causes DNA damage in the cerebellum and cerebral cortex of mice in a dose-dependent manner. Verazine can be used in the study of fungal infections and neurological diseases .

Cat. No.	Product Name	Application	Reactivity

HY-P81385

Amyloid Precursor Protein Antibody (YA1130) APP; A4; AD1; Amyloid beta A4 protein; ABPP; APPI; APP; Alzheimer disease amyloid protein; cerebral vascular amyloid peptide; CVAP; PreA4; Protease nexin-II; PN-II	IHC-P	Human

HY-P82823

Phospho-Amyloid Precursor Protein (Thr743) Antibody (YA2568) APP; A4; AD1; Amyloid beta A4 protein; ABPP; APPI; APP; Alzheimer disease amyloid protein; cerebral vascular amyloid peptide; CVAP; PreA4; Protease nexin-II; PN-II	WB, ICC/IF, IP	Human, Rat

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Antibodies

Name
Email *

	Sorry, but the email address you supplied was invalid.

cerebral disease

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

NaturalProducts

Antibodies

Natural
Products